| PRECLINICAL | evidence | Therapeutic Landscape Evolution: From Lifestyle Interventions to Precision Pharmacotherapy. | Semaglutide | — | 2026-04-03 |
| PRECLINICAL | evidence | Sex-specific metabolic responses to glucagon receptor agonism and modulation of the FGF21-glucagon axis in female mice. | Semaglutide | — | 2026-04-03 |
| PRECLINICAL | evidence | Effect of Semaglutide on Body Weight, Blood Lipid Profile, and Adipokine Status in Obese Patients. | Semaglutide | — | 2026-04-02 |
| PRECLINICAL | evidence | The Role of GLP1 Receptor Agonists and Multi-agonist Incretin Therapies for Specific Obesity-related Health Conditions: Evidence and Rationale for Prioritisation. | Wegovy | Weight & fat loss | 2026-04-02 |
| PRECLINICAL | evidence | Predictors and Characteristics of Hair Loss Among Users of GLP-1 Receptor Agonists: A Cross-Sectional Analysis. | Ozempic | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Impact of GLP-1 and dual agonists on the incidence of new cases of physician-reported sleep apnea: a real-world study. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk? | Semaglutide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Responses to GLP-1RA in White and Black Adults With Obesity: Insights From Generalized Additive Mixed Models of EHR Data. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide as a potential tool in pre-lung transplant weight loss optimization. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | GLP-1 receptor agonists and immune checkpoint inhibitor therapy: a narrative review on mechanistic and clinical evidence. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Targeting Multiple Gut-Brain Pathways in Obesity: Rationale for Combination Pharmacotherapy. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Reply: Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan(R) in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide in Frail HFpEF: Need for Objective Functional Measures and Body Composition Assessment. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults. | Semaglutide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | [Current and future medical treatments for metabolic dysfunction-associated steatohepatitis]. | Semaglutide | Liver health | 2026-04-01 |
| PRECLINICAL | evidence | Association Between GLP-1RAs and Postoperative Complications Following Operative Ankle Fracture Fixation: A Retrospective Cohort Study. | Ozempic | — | 2026-04-01 |
| PRECLINICAL | evidence | The ESSENCE of hope: what semaglutide's Food and Drug Administration approval means for metabolic dysfunction-associated steatohepatitis. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Evaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Dercum Disease: Exploratory Therapeutic Approaches in the Absence of Standardized Medical Treatment-A Single Center Case Series. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Quality by Design-Based Formulation Development of an Oral Semaglutide Tablet. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). | Semaglutide | Liver health | 2026-04-01 |
| PRECLINICAL | evidence | Obesity Management: Pharmacotherapy. | Semaglutide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | [Weight Recurrence After Bariatric Surgery: Definitions, Diagnosis, and Management Strategies. Part 2]. | Semaglutide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | White matter hyperintensities in Alzheimer's disease in the era of anti-amyloid therapies. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study. | Ozempic | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Thyroid Function Tests: A Systematic Review Identifying a Critical Evidence Gap. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | A Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity. | Wegovy | — | 2026-04-01 |
| PRECLINICAL | evidence | Semaglutide in Metabolic Medicine: A Review on Clinical Applications and Emerging Therapeutics. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Initiators of Semaglutide in General Practice in New South Wales, 2020-2023: A Retrospective Cohort Study. | Ozempic | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Glucagon like peptide-1 receptor agonist (Ozempic): Revolutionising chronic kidney disease management in diabetes. | Ozempic | — | 2026-04-01 |
| PRECLINICAL | evidence | Significant improvement of postural orthostatic tachycardia syndrome (POTS) with semaglutide: a case report. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Cost-effectiveness analysis of oral semaglutide versus subcutaneous dulaglutide in patients with type 2 diabetes mellitus: A Markov model study. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Trends in Use of Obesity Medications and Metabolic and Bariatric Surgery Among All of Us Participants From 2003 to 2023. | Semaglutide | Weight & fat loss | 2026-04-01 |
| PRECLINICAL | evidence | Clinical Efficacy of a Flavo-Proxylane Topical Regimen Pre- and Post-ultrasound Procedure for Subjects Undergoing Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Therapy. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Metabolite Profiling and Identification of Semaglutide in Liver S9 Across Species and Rat Plasma. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Comparison of Pediatric and Adult Glucagon-Like Peptide-1 Receptor Agonist Exposures Reported To United States Poison Centers, 2017-2024. | Semaglutide | — | 2026-04-01 |
| PRECLINICAL | evidence | Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer. | Semaglutide | Glycemic control | 2026-04-01 |
| PRECLINICAL | evidence | Cost-Effectiveness of Highly Effective Glucose-Lowering Agents: Do Current Practices Optimize Clinical and Economic Outcomes? | Semaglutide | — | 2026-04-01 |